count. To study this issue, we retrospectively examined 286 consecutive patients undergoing autologous progenitor cell chemotherapeutic preparative regimen and all received an autologous transplant using PBPC alone. The transplantation at our institution from 1 January l994 to 1 June l996 to analyze whether the platelet count at the median time to a platelet count of 20 × 10 9 /l was 13 days. Patients beginning the transplant with a less than nortime of transplantation correlated with either platelet engraftment, or the number of transfusion events required mal platelet count (less than 150 × 10 9 /l) engrafted in 17 days, and received a median number of seven platelet during the transplant. transfusions, as compared with platelet engraftment of 12 days, and four platelet transfusions, for patients beginning the transplant with a normal platelet count Materials and methods (P = 0.001). Both groups of patients received an equivalent dose of CD34 + cells. We conclude that thrombocyto-
Patient characteristics penia at the initiation of autologous transplantation is
From 1 January l994 to 1 June l996, 286 consecutive adult associated with increased platelet transfusion requirepatients underwent high-dose chemotherapy with autologments, independent of the dose of CD34 + cells infused. ous progenitor cell transplantation at the Cleveland Clinic Keywords: autologous marrow transplantation; stem Foundation. Patient characteristics are shown in Table 1 . cells; platelet transfusions PBPC collection and processing Platelet engraftment following autologous bone marrow All patients received cytokine priming for PBPC collection, transplantation (ABMT) historically occurred 4-5 weeks with G-CSF 5-10 g/kg per day subcutaneously for 8-10 days, with PBPC collection beginning on day +5. Total yield of PBPC collected was at least 2 × 10 6 CD34 + cell/kg. Bu-Cy-VP = busulfan, cyclophosphamide, etoposide; Bu-Cy = busulfan, cyclophosphamide; Ctx-Carbo-TT = cyclophosphamide, carboplatin, thiotepa; Ctx-Plat-BCNU = cyclophosphamide, cisplatin, BCNU.
patients were harvested on a COBE Spectra leukapheresis generally for testicular cancer. G-CSF was routinely given at a dose of 5 g/kg per day beginning 4 h after the infusion machine (COBE, Denver, CO, USA).
of PBPC. G-CSF was discontinued after patients reached 1.0 × 10 9 /l neutrophils/mm 3 on 2 consecutive days.
CD34
+ analysis
Peripheral blood progenitor cells obtained by apheresis Supportive care were collected into ACD-A anticoagulant. An aliquot of each collection was counted and a minimum of 20 × 10 6 Patients received prophylactic antibiotics consisting of oral acyclovir, ciprofloxacin, and low-dose Amphotericin B (0.2 cells were submitted for flow cytometric evaluation. For each sample, 250 000 events were required as list mode mg/kg), beginning on the day after PBPC infusion. Patients experiencing persistent fevers had their antibiotic coverage data using a Cell Quest (BDIS, San Jose, CA, USA) software document which had been specifically tailored and broadened. Patients received red blood cell transfusions to maintain a hemoglobin greater than 9 gm/dl. Platelet transstored for this purpose. Total CD34 + cells were calculated by multiplying the percentage of CD34
+ -positive cells in fusions were given for platelet counts less than 10 × 10 9 /l or for clinical bleeding. A platelet transfusion event was the flow cytometric analysis by the total number of nucleated cells in the apheresis product. This number was either with single donor infusions, or pooled platelets (pooled platelets generally consisted of six pooled units divided by the patient's actual weight to give the total CD34 + cells per kilogram. of platelets).
Definitions Transplant protocol
Ninety-nine percent of patients were treated with one of Platelet engraftment was defined as a platelet count of 20 × 10 9 /l independent of platelet transfusions. A platelet four chemotherapy (only) preparative regimens: cyclophosphamide, thiotepa, carboplatin (cyclophosphamide 1500 mg transfusion 'event' was any infusion of platelets, either pooled or a single donor. per m 2 daily × 4 days; thiotepa 125 mg per m 2 daily × 4 days; carboplatin 200 mg per m 2 daily × 4 days); busulfan, For the purposes of this study, the platelet count was deemed normal (150 × 10 9 /l or greater), or abnormal, on cyclophosphamide, VP-16, (busulfan 14 mg/kg, etoposide 50 mg/kg, cyclophosphamide 120 mg/kg); busulfan and the day of initiation of high-dose chemotherapy. Thus, all patients had already received cytokine priming and the colcyclophosphamide (busulfan 16 mg/kg, cyclophosphamide 120 mg/kg); cyclophosphamide, cisplatin, BCNU lection of peripheral progenitor cells, at the time of evaluation of a normal or abnormal platelet count. The apheresis (cyclophosphamide 1875 mg/m 2 per day × 3 days; cisplatin 55 mg/m 2 per day × 3 days; BCNU 600 mg per m 2 ). Four to collect CD34 + cells occurred 5-10 days prior to the initiation of the preparative regimen. patients (1%) received other chemotherapeutic regimens, groups was also statistically significant in this multivariate analysis, with patients presenting with thrombocytopenia (group A) being a significant factor in terms of platelet engraftment (P = 0.02).
Statistical analysis
Group A patients also required more platelet transfusions than did group B, as shown in Table 3 (P = 0.001). We then A Wilcoxon rank sum test was used when engraftment time performed a multivariate analysis of variables affecting the (days) for CD34
+ cell dose was compared for two groups. number of transfusions required during the transplant, A Kruskal-Wallis test was used if more than two groups including CD34 + dose, underlying diagnosis, sex, age, prior were being compared. A P value of 0.05 or less was conexposure to radiation therapy, number of courses of prior sidered to be statistically significant. A forward stepwise chemotherapy, and preparative regimen in the multiple regression was used to see what factors were independently regression model. Group A vs group B patients was a sigassociated with the number of transfusions and days to nificant factor in this model (P = 0.001), as was age at platelet engraftment. A significance level of 0.05 was used transplant, with older age resulting in a higher platelet as the entry criterion.
transfusion requirement (P = 0.04). A box plot of the number of platelet transfusions by platelet count is shown in Figure 1 .
Results
We next examined the results of engraftment and transfusion requirements comparing those patients with a plateSeventy-four patients began the transplant with an abnorlet count of less than 100, with patients with a platelet count mally low platelet count (defined as less than 150 × 10 9 /l), of 100-149. Only 28 patients began the transplant with a and 212 patients began the transplant with a normal platelet platelet count of less than 100; the median number of transcount. The number of courses of prior chemotherapy, as fusions was 7.5, and the median time of platelet well as the number of CD34 + cells harvested, is shown in engraftment was l9 days. These were not statistically sig- Table 2. nificant differences when compared with patients entering Table 3 shows engraftment and transfusion results for the transplant with a platelet count of 100-149, requiring both treatment groups. Patients presenting with thrombocya median six transfusion events, and experiencing platelet topenia at the time of transplant experienced a longer time engraftment in 16 days. We further analyzed patients with to platelet engraftment, as compared with patients a normal platelet count, comparing those with a platelet presenting with a normal platelet count. This was true count of 150-250 thousand (n = 152) with those with a despite the fact that group A patients actually received a platelet count greater than 250 × 10 9 /l (n = 60). The time higher number of CD34 + cells per kilogram infused than to engraftment was identical between these two groups (median 12 days and mean 17 days). The group with a The use of PBPC, with or without the use of autologous bone marrow, has dramatically shortened platelet bleeding. Additionally, different transplant centers employed different criteria to initiate a platelet transfusion, with the platelet trigger values ranging 10-25 × 10 9 /l. A summary of studies reporting platelet transfusion requirements during autologous transplantation with PBPC support is shown in Table 4 . While days to platelet engraftment are fairly consistent over these series, there is a wide range in the number of platelet transfusions reported. This may reflect the fact that a platelet transfusion event may consist of pooled platelets, which is made up of four to eight individual units. Different institutional guidelines concerning platelet transfusions also clearly contribute to these discrepancies.
We found a difference in the number of platelet trans- men. From an engraftment perspective, the number of CD34 + cells was the most important variable in the multivariate analysis. However, the pretransplant platelet count engraftment after autologous transplantation. Historically, was also a statistically important variable within this multia period of 4-5 weeks was required to achieve a platelet variate model. Additionally, patients presenting with thromcount of 20 × 10 9 /l after ABMT. The use of the hematopobocytopenia required more transfusions than did those ietic growth factors after autologous marrow transplantation presenting with a normal platelet count. The latter point is had been shown to enhance neutrophil engraftment, but not possibly intuitive, as those presenting with thrombocytoto affect platelet engraftment. [13] [14] [15] [16] Numerous reports have penia frequently experience a more rapid initial platelet demonstrated that primed PBPC have dramatically shortnadir, and thus the initiation of platelet transfusions began ened time of platelet engraftment, with most reports sooner in their transplant course. However, the explanation reporting platelet independence in 12-18 days following for prolonged platelet engraftment is less obvious and any infusion of autologous progenitor cells, with or without explanation for this phenomenon is conjectural. It is possautologous marrow. [3] [4] [5] [6] [7] [8] ible that patients presenting with thrombocytopenia might Many studies have shown that engraftment of neutrophils have a more damaged bone marrow microenvironment and platelets correlates with the number of progenitor cells from prior chemotherapy and/or radiation therapy. Bone infused. The number of circulating progenitor cells is roumarrow microenvironment differences might potentially tinely measured by quantifying CD34
+ cells with multiexplain a difference in the speed of platelet recovery. It color flow cytometry. Transplant centers frequently employ might be possible that different patient populations have a threshold number of CD34 + cells/kg to determine different levels of circulating megakaryocytic stimulating adequate collection of progenitor cells. While many studies cytokines, both pre-and post-transplantation. Immunologic have reported time to platelet engraftment when using abnormalities resulting in thrombocytopenia pre-BMT PBPC, relatively few series have reported specific data of might persist post-BMT, resulting in prolonged time to number of platelet transfusions required during autologous engraftment, as well as decreased platelet life span of transtransplantation. The reported data are complicated by the fused platelets during the period of thrombocytopenia. The fact that there is a lack of a standardization of what defines two patient groups behaved identically clinically, in our a platelet transfusion, as some centers exclusively utilize study, so we do not think that our results are due to the single donor platelets, while others prefer to transfuse thrombocytopenic group having more infections, bleeding, pooled platelets. The utility of platelet transfusions is clearly affected by clinical variables, such as fevers and or other readily clinically apparent variables. human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. New Engl J Med
